ASMB - Assembly Biosciences Inc Stock Price, Fair Value and News

$15.04+0.32 (+2.17%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ASMB Price Action

Last 7 days

-6.8%

Last 30 days

-9.4%

Last 90 days

2.9%

Trailing 12 Months

92.8%

ASMB RSI Chart

ASMB Valuation

Market Cap

95.6M

Price/Earnings (Trailing)

-2.34

Price/Sales (Trailing)

3.61

EV/EBITDA

-1.47

Price/Free Cashflow

4.19

ASMB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ASMB Fundamentals

ASMB Revenue

Revenue (TTM)

26.5M

Rev. Growth (Yr)

989.97%

Rev. Growth (Qtr)

-19.78%

ASMB Earnings

Earnings (TTM)

-40.8M

Earnings Growth (Yr)

33.34%

Earnings Growth (Qtr)

13.8%

ASMB Profitability

EBT Margin

-172.50%

Return on Equity

-156.92%

Return on Assets

-40.7%

Free Cashflow Yield

23.89%

ASMB Investor Care

Shares Dilution (1Y)

16.08%

Diluted EPS (TTM)

-6.92

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	13.7M	20.3M	26.5M	0
2023	6.8M	6.9M	7.0M	7.2M
2022	6.4M	0	6.5M	6.6M
2021	54.8M	0	30.5M	6.3M
2020	16.2M	52.5M	82.8M	79.1M
2019	15.1M	15.0M	14.9M	16.0M
2018	11.9M	12.8M	14.4M	14.8M
2017	3.0M	6.0M	7.5M	9.0M
2016	1.7M	1.9M	1.8M	1.5M
2015	185.7K	360.0K	827.5K	1.2M
2014	192.7K	184.3K	176.0K	167.7K
2013	0	0	0	201.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Assembly Biosciences Inc

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

CEO	Mr. Jason A. Okazaki
WEBSITE	assemblybio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	70

Assembly Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Assembly Biosciences Inc? What does ASMB stand for in stocks?

ASMB is the stock ticker symbol of Assembly Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Assembly Biosciences Inc (ASMB)?

As of Fri Nov 22 2024, market cap of Assembly Biosciences Inc is 95.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ASMB stock?

You can check ASMB's fair value in chart for subscribers.

Is Assembly Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether ASMB is over valued or under valued. Whether Assembly Biosciences Inc is cheap or expensive depends on the assumptions which impact Assembly Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASMB.

What is Assembly Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 22 2024, ASMB's PE ratio (Price to Earnings) is -2.34 and Price to Sales (PS) ratio is 3.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASMB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Assembly Biosciences Inc's stock?

In the past 10 years, Assembly Biosciences Inc has provided -0.175 (multiply by 100 for percentage) rate of return.